Literature DB >> 2692916

Adjuvant chemotherapy and endocrine therapy for node-positive and node-negative breast carcinoma.

K S Albain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2692916     DOI： 10.1097/00003081-198912000-00026

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN： 0009-9201            Impact factor:   2.190


× No keyword cloud information.
  2 in total

1.  Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.

Authors:  K S Albain; S Green; M LeBlanc; S Rivkin; J O'Sullivan; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.

Authors:  Y Park; K Okamura; S Mitsuyama; T Saito; J Koh; S Kyono; K Higaki; M Ogita; T Asaga; H Inaji; H Komichi; N Kohno; K Yamazaki; F Tanaka; T Ito; H Nishikawa; A Osaki; H Koyama; T Suzuki
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.